ArticleCancers2022
Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Routine Lymph Node Dissection in the Surgical Treatment of Primary Liver Tumors: a Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Pooled it
- Anatomic-Biologic Borderline Resectability Criteria Improve Recurrence Risk Stratification in Perihilar Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Redefining precision in biliary surgery: a paradigm shift from operative mastery to prognostic-driven strategy.Frontiers in surgery · 2026Article
- Prognostic implications of morphological subtypes in a surgical cohort of perihilar cholangiocarcinoma: the overriding impact of nodal status.International journal of clinical oncology · 2025Article
- Endoscopic Ultrasound for Nodal Staging in Patients with Resectable Cholangiocarcinoma.Journal of clinical medicine · 2025Article
- Development and validation of a machine learning-based nomogram for survival prediction of patients with hilar cholangiocarcinoma after curative-intent resection.Scientific reports · 2025Article
- Minimally Invasive Surgery for Perihilar Cholangiocarcinoma-A Review of the Current Literature.Journal of clinical medicine · 2025Review
- Improving postoperative survival in cholangiocarcinoma: development of surgical strategies with a screening program in the epidemic region.World journal of surgical oncology · 2024Article
- Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease.Annals of surgical oncology · 2024Article
- ASO Author Reflections: Palliative Therapy Might be an Alternative When the Risks of Surgery for Perihilar Cholangiocarcinoma are High.Annals of surgical oncology · 2024Article
- Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic.BMC cancer · 2024Article
- Adjuvant therapy of biliary tract cancers.Therapeutic advances in medical oncology · 2023Review
- Article
- Perihilar-cholangiocarcinoma: what really matters?Hepatobiliary surgery and nutrition · 2022Article
- Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center.Current oncology (Toronto, Ont.) · 2022Article
- Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma.Journal of personalized medicine · 2022Review
- Multimodal treatment and tumour biology-driven long-term survival in PSC-associated hilar cholangiocarcinoma: A case report.Medicine internationalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 12 institutions in 6 countries.
Funding
Abstract
Background: Lymph node metastasis and positive resection margins have been reported to be major determinants of overall survival (OS) and poor recurrence-free survival (RFS) for patients who underwent resection for perihilar cholangiocarcinoma (pCCA). However, the prognostic value of positive lymph nodes independently from resection margin status on OS has not been evaluated. Methods: From the European Cholangiocarcinoma (ENSCCA) registry, patients who underwent resection for pCCA between 1994 and 2021 were included in this retrospective cohort study. The primary outcome was OS stratified for resection margin and lymph node status. The secondary outcome was recurrence-free survival. Results: A total of 325 patients from 11 different centers and six European countries were included. Of these, 194 (59.7%) patients had negative resection margins. In 113 (34.8%) patients, positive lymph nodes were found. Lymph node status, histological grade, and ECOG performance status were independent prognostic factors for survival. The median OS for N0R0, N0R1, N+R0, and N+R1 was 38, 30, 18, and 12 months, respectively (p < 0.001). Conclusion: These data indicate that in the presence of positive regional lymph nodes, resection margin status does not determine OS or RFS in patients with pCCA. Achieving negative margins in patients with positive nodes should not come at the expense of more extensive surgery and associated higher mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.